Please login to the form below

Not currently logged in
Email:
Password:

Takeda wins UK approval for cancer drug

Takeda's bone cancer treatment Mepact has won the backing of the UK's National Institute for Health and Clinical Excellence

Takeda Pharmaceutical won the backing of the UK's National Institute for Health and Clinical Excellence (NICE) for its Mepact (mifamurtide) drug, for the treatment of high-grade resectable non-metastic osteosarcoma.

Mepact is approved for use with chemotherapy after surgery for bone cancers that have not spread. The approval is conditional on Takeda providing a price discount, which it has agreed to do, according to NICE.

The agency reversed a decision from 2010 in which it rejected the drug. The initial economic analysis may not have adequately captured the health-related quality of life from the drug, NICE said.

The terms of the discount have not been disclosed at Takeda's request.

Takeda acquired the rights to Mepact when it purchased IDM Pharma in May, 2009.

7th September 2011

From: Healthcare

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
nitrogen

nitrogen is a strategic brand experience agency which blends science and imagination; delivering multi-channel communications that are both compelling and...

Latest intelligence

Cell and gene therapies: on course for commercial success?
...
eyeforpharma_h_logo.png
Make Anthill your strategic partner in Barcelona
We are excited to attend and exhibit at eyeforpharma Barcelona 2017 (March 14-16th), and present two multichannel strategy workshops....
Why we need to bring empathy back into medcomms
Medical communications requires you to bring more empathy to your communications...

Infographics